Ann: Increased Scheme Consideration from Pfizer, page-56

Personally I think this revision is enough to get me over the line. I'm going to vote a YES on this.

For several reasons:

1) Loss of confidence in the current BOD (they are not looking after SH best interests nor does it seem like they're pushing to achieve true market penetration and revenue)
2) To recoup most of my initial investment (during these market conditions it's somewhat a blessing in disguise)
3) The pathway to commercialisation for RAP isn't looking too good although they like to dress it up as such.

I feel like being a LTH of RAP for all these years has not been worth it at all. Time to go.